Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × HCC × lenvatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 36 Cholangiocarcinoma 12 Carcinoma, Renal Cell 9 Liver Neoplasms 5 Stomach Neoplasms 4 Biliary Tract Neoplasms 4 Uterine Cervical Neoplasms 3 Neoplasms 3 Endometrial Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Vulvar Neoplasms 2 Triple Negative Breast Neoplasms 2 Thyroid Neoplasms 2 Small Cell Lung Carcinoma 2 Recurrence 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Neoplasm Metastasis 2 Liver Diseases 2 Kidney Neoplasms 2 Cirrhosis, Familial, with Pulmonary Hypertension 2 Breast Neoplasms 2 Biliary Tract Neoplasms Immunotherapy 2 Advanced Solid Tumor 2 von Hippel-Lindau Disease 1 Thyroid Carcinoma, Anaplastic 1 Thymoma 1 Solid Tumor, Adult 1 Solid Tumor 1 Sarcoma 1 Pancreatic Neoplasms 1

Interventions

nimotuzumab 1 lenvatinib 1 atezolizumab 1 Tirapazamine 1 Sorafenib 1 Radiotherapy 1 Radiosurgery 1 Immune Checkpoint Inhibitors 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05873244 2025-03-21

CXD101 in Immunotherapy-related Liver Cancer

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡